American Conference Institute (ACI) will be holding its 3rd Annual Paragraph IV Disputes master symposium from September 30 to October 1, 2014 in Chicago, IL. ACI faculty will provide insights into:
• Paragraph IV Due Diligence Strategies Analyses
• Pending Patent Reform Legislation and Its Potential Impact on Hatch-Waxman Litigation
• Personal and General Jurisdiction Challenges Under Daimler and Mylan
• IPR, CBM, and PGR Utilization in ANDA Litigation
• FRCP 16 and 26 Discovery Dilemmas Relative to Scheduling Orders, Protective Orders and ESIs in ANDA Litigation
• Myriad 101 Rejections and Nautilus 112 Indefiniteness Findings
• Barraclude and New Obviousness Considerations
• The Merits of Bringing A Declaratory Judgment Action in a Paragraph IV Case
• Settlement Strategies Post-Actavis
• At-Risk Launches and Damages
• Markman strategies post–Teva v. Sandoz
• Willfulness and recklessness considerations in relation to ANDA filing
The conference will offer presentations on the following topics:
• Paragraph IV Due Diligence Analysis: Economic Impact of Pharmaceutical Patent Wins and Losses at District Courts and PTAB
• Patents, Politics, Trolls and System Abuse: An Update on How Proposed Patent Reform Legislation May Impact the Patent End Game
• Establishing Personal and General Jurisdiction in A Paragraph IV Case in the Aftermath of Daimler and Mylan
• RCP 16 and 26: Brand and Generic Viewpoints on Scheduling Orders, Protective Orders and ESIs in a Hatch-Waxman Setting
• Obviousness of the Unexpected: Understanding How a Compound Patent Defeat in Baraclude May Raise New Questions for Prior Art
• PTO Proceedings Update: The Continuing Use of IPR, PGR and CBM Review in the Hatch-Waxman Arena
• A Hatch-Waxman Practitioner's Guide to The Patent Trial and Appeals Board: The PTAB Live
• A View From the Bench: The Judges Speak
• Myriad and Nautilus: Exploring New Paragraph IV Invalidity Challenges Under 101 and 112
• Re-Evaluating Claim Construction and Markman Strategies in Wake of Teva v. Sandoz
• Evaluating the Merits of Bringing A Declaratory Judgment Action in a Paragraph IV Case: Duplication or Necessity?
• FTC Keynote: Reverse Payment Settlements and Other Antitrust Concerns Impacting Paragraph IV Litigation in the Wake of Actavis
• Developing Practical Strategies for Settling A Paragraph IV Case Post-Actavis: A Litigator's Perspective
• FDA Update: Survey of Agency Activity Impacting Paragraph IV Litigation
• Assessing the True Measure of Damages in At-Risk Launch Scenario
• The Ethics of Paragraph IV Practice: New Developments Impacting Professional Responsibility in the Hatch-Waxman Arena
In addition, two post-conference workshops will be offered on October 2, 2014. The first, entitled "PTO Practice Master Class: Anatomy of a PTO PTAB Patent Trial in the Hatch-Waxman Arena" will be offered from 8:30 am to 12:30 pm, and the second, entitled "Biosimilars Boot Camp for the Paragraph IV Litigator," will be offered from 1:00 to 4:30 pm.
The agenda for the Paragraph IV Disputes master symposium can be found here. More information regarding the workshops can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee for the conference is $2,295 (conference alone), $2,895 (conference and one workshop), or $3,495 (conference and both workshops). Those interested in registering for the conference can do so here, by e-mailing [email protected], by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Comments